Amneal (AMRX) Co-CEO awarded time- and performance-based RSUs

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Patel Chirag K. reported acquisition or exercise transactions in this Form 4 filing.

Amneal Pharmaceuticals reported that President and Co-CEO Chirag K. Patel received equity awards in the form of restricted stock units. He was granted 190,632 time-based restricted stock units, each representing a right to receive one share of Class A common stock, vesting in four equal annual installments beginning on March 2, 2027.

He also received 354,031 performance-based restricted stock units, tied to the company’s average closing share price over a three-year performance period. The number of shares ultimately delivered may range from 0% to 200% of the target, with any earned units vesting in full on February 28, 2029, and the table reflecting the maximum shares issuable.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Patel Chirag K.

Role President & Co-CEO

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	190,632	$0.00	--
Grant/Award	Performance-Based Restricted Stock Units	354,031	$0.00	--

Holdings After Transaction: Restricted Stock Units — 190,632 shares (Direct); Performance-Based Restricted Stock Units — 354,031 shares (Direct)

Footnotes (1)

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. The restricted stock units vest in four equal annual installments beginning on March 2, 2027. Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Represents a performance-based restricted stock unit grant of 354,031 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period.

Form 4 Insider Transactions: What Each Field Means →

03/03/2026 - 04:29 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patel Chirag K.

(Last)

(First)

(Middle)

C/O AMNEAL PHARMACEUTICALS, INC.

400 CROSSING BOULEVARD

(Street)

BRIDGEWATER

08807

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Amneal Pharmaceuticals, Inc. [ AMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President & Co-CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	03/02/2026		A		190,632		⁽²⁾	⁽²⁾	Class A Common Stock	190,632	$0	190,632	D
Performance-Based Restricted Stock Units	⁽³⁾	03/02/2026		A		354,031		⁽⁴⁾	⁽⁴⁾	Class A Common Stock	354,031	$0	354,031	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

2. The restricted stock units vest in four equal annual installments beginning on March 2, 2027.

3. Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

4. Represents a performance-based restricted stock unit grant of 354,031 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period.

Remarks:

	/s/ Denis Butkovic, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What equity awards did Amneal (AMRX) President & Co-CEO Chirag K. Patel receive?

Chirag K. Patel received 190,632 time-based restricted stock units and 354,031 performance-based restricted stock units. Each unit represents a contingent right to one share of Amneal Class A common stock, subject to time-based vesting and share price performance conditions.

How do Chirag K. Patel’s time-based RSUs at Amneal (AMRX) vest?

The 190,632 time-based restricted stock units vest in four equal annual installments beginning March 2, 2027. Each vesting date delivers shares of Class A common stock, provided service-based conditions are satisfied through each anniversary of the grant date.

What are the performance conditions for Amneal (AMRX) performance-based RSUs granted to Chirag K. Patel?

The 354,031 performance-based restricted stock units vest based on Amneal’s Class A common stock achieving specified average closing price targets over a three-year performance period. Earned units, if any, vest in full on February 28, 2029, at 0%–200% of target shares.

What is the maximum number of Amneal (AMRX) shares issuable under Chirag K. Patel’s performance-based RSU award?

The filing states the number of performance-based restricted stock units reported, 354,031, represents the maximum shares issuable under the award. Actual shares delivered depend on achieving the specified stock price performance conditions during the three-year performance period.

Does Chirag K. Patel pay a purchase price for the Amneal (AMRX) RSUs granted?

The reported transactions show a price per unit of $0.0000, indicating these are grant or award acquisitions rather than open-market purchases. Value to Chirag K. Patel depends on future vesting of the restricted stock units and Amneal’s share price at that time.